Compare Stocks: TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAH Cardinal Health	$246.67 -0.8%	$234.23	$145.87 ▼ $258.30	$57.82B	0.51	1.70 million shs	1.55 million shs
COR Cencora	$330.52 -2.0%	$312.33	$244.82 ▼ $377.54	$64.35B	0.57	1.26 million shs	1.02 million shs
CVS CVS Health	$96.80 -0.4%	$100.79	$69.51 ▼ $110.68	$124.32B	0.59	7.08 million shs	4.48 million shs
JNJ Johnson & Johnson	$275.12 -1.2%	$261.98	$173.33 ▼ $281.07	$670.99B	0.24	6.40 million shs	4.04 million shs
MCK McKesson	$907.35 -1.5%	$848.13	$682.35 ▼ $999.00	$107.42B	0.3	940,694 shs	851,413 shs
SAN Banco Santander	$14.90 -1.0%	$14.19	$9.48 ▼ $15.05	$219.31B	0.74	18.90 million shs	8.28 million shs
SNY Sanofi	$44.24 -0.2%	$43.92	$40.89 ▼ $52.68	$107.26B	0.35	2.31 million shs	1.69 million shs
SNYNF Sanofi	$89.27	$87.38	$80.74 ▼ $106.34	N/A	N/A	30,337 shs	121 shs
TEV Tervita		C$0.00	C$1.69 ▼ C$6.46	C$672.00M	N/A	79,738 shs	15,893 shs
TEVA Teva Pharmaceutical Industries	$36.36 -0.7%	$34.64	$18.21 ▼ $38.37	$42.67B	0.87	5.12 million shs	7.40 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAH Cardinal Health	-0.89%	+5.09%	+3.07%	+19.87%	+63.97%
COR Cencora	-1.86%	+2.61%	+4.04%	+20.22%	+12.11%
CVS CVS Health	-0.35%	+3.92%	-2.46%	+0.72%	+32.00%
JNJ Johnson & Johnson	-1.27%	+2.54%	+6.73%	+18.18%	+54.82%
MCK McKesson	-1.56%	+1.31%	+3.81%	+16.85%	+31.48%
SAN Banco Santander	-0.86%	+1.43%	+1.74%	+22.58%	+57.76%
SNY Sanofi	-0.20%	-1.29%	+3.41%	-1.73%	-11.32%
SNYNF Sanofi	0.00%	-2.01%	+7.43%	+1.78%	-10.44%
TEV Tervita	0.00%	0.00%	0.00%	0.00%	0.00%
TEVA Teva Pharmaceutical Industries	-0.60%	-0.25%	+4.68%	+6.28%	+93.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAH Cardinal Health	$246.67 -0.8%	$234.23	$145.87 ▼ $258.30	$57.82B	0.51	1.70 million shs	1.55 million shs
COR Cencora	$330.52 -2.0%	$312.33	$244.82 ▼ $377.54	$64.35B	0.57	1.26 million shs	1.02 million shs
CVS CVS Health	$96.80 -0.4%	$100.79	$69.51 ▼ $110.68	$124.32B	0.59	7.08 million shs	4.48 million shs
JNJ Johnson & Johnson	$275.12 -1.2%	$261.98	$173.33 ▼ $281.07	$670.99B	0.24	6.40 million shs	4.04 million shs
MCK McKesson	$907.35 -1.5%	$848.13	$682.35 ▼ $999.00	$107.42B	0.3	940,694 shs	851,413 shs
SAN Banco Santander	$14.90 -1.0%	$14.19	$9.48 ▼ $15.05	$219.31B	0.74	18.90 million shs	8.28 million shs
SNY Sanofi	$44.24 -0.2%	$43.92	$40.89 ▼ $52.68	$107.26B	0.35	2.31 million shs	1.69 million shs
SNYNF Sanofi	$89.27	$87.38	$80.74 ▼ $106.34	N/A	N/A	30,337 shs	121 shs
TEV Tervita		C$0.00	C$1.69 ▼ C$6.46	C$672.00M	N/A	79,738 shs	15,893 shs
TEVA Teva Pharmaceutical Industries	$36.36 -0.7%	$34.64	$18.21 ▼ $38.37	$42.67B	0.87	5.12 million shs	7.40 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAH Cardinal Health	-0.89%	+5.09%	+3.07%	+19.87%	+63.97%
COR Cencora	-1.86%	+2.61%	+4.04%	+20.22%	+12.11%
CVS CVS Health	-0.35%	+3.92%	-2.46%	+0.72%	+32.00%
JNJ Johnson & Johnson	-1.27%	+2.54%	+6.73%	+18.18%	+54.82%
MCK McKesson	-1.56%	+1.31%	+3.81%	+16.85%	+31.48%
SAN Banco Santander	-0.86%	+1.43%	+1.74%	+22.58%	+57.76%
SNY Sanofi	-0.20%	-1.29%	+3.41%	-1.73%	-11.32%
SNYNF Sanofi	0.00%	-2.01%	+7.43%	+1.78%	-10.44%
TEV Tervita	0.00%	0.00%	0.00%	0.00%	0.00%
TEVA Teva Pharmaceutical Industries	-0.60%	-0.25%	+4.68%	+6.28%	+93.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAH Cardinal Health	2.84	Moderate Buy	$266.56	8.06% Upside
COR Cencora	2.81	Moderate Buy	$370.85	12.20% Upside
CVS CVS Health	2.92	Moderate Buy	$106.83	10.37% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$272.83	-0.83% Downside
MCK McKesson	2.78	Moderate Buy	$973.44	7.28% Upside
SAN Banco Santander	2.50	Moderate Buy	N/A	N/A
SNY Sanofi	2.40	Hold	$49.50	11.89% Upside
SNYNF Sanofi	0.00	N/A	N/A	N/A
TEV Tervita	0.00	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.90	Moderate Buy	$42.89	17.96% Upside

Current Analyst Ratings Breakdown

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	MCK McKesson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/4/2026	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $48.00
9/3/2026	CVS CVS Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$126.00 ➝ $118.00
9/2/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$280.00 ➝ $320.00
8/26/2026	CVS CVS Health	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/21/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/19/2026	CAH Cardinal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B+) ➝ Buy (B)
8/19/2026	MCK McKesson	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$925.00 ➝ $1,000.00
8/19/2026	COR Cencora	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$330.00
8/19/2026	MCK McKesson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$845.00
8/19/2026	CAH Cardinal Health	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform ➝ Outperform	$276.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAH Cardinal Health	$254.25B	0.23	$15.35 per share	16.07	($11.71) per share	-21.06
COR Cencora	$321.33B	0.20	$21.19 per share	15.60	$16.97 per share	19.48
CVS CVS Health	$402.07B	0.31	$14.82 per share	6.53	$62.47 per share	1.55
JNJ Johnson & Johnson	$94.19B	7.04	$13.95 per share	19.72	$35.26 per share	7.80
MCK McKesson	$410.98B	0.26	$44.87 per share	20.22	($33.14) per share	-27.38
SAN Banco Santander	$61.87B	3.54	$1.30 per share	11.46	$9.17 per share	1.62
SNY Sanofi	$48.92B	2.19	$7.06 per share	6.27	$33.36 per share	1.33
SNYNF Sanofi	N/A	N/A	N/A	N/A	N/A	N/A
TEV Tervita	C$1.36B	0.00	N/A	29.62	C$1.58 per share	0.00
TEVA Teva Pharmaceutical Industries	$17.26B	2.46	$3.70 per share	9.82	$6.66 per share	5.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAH Cardinal Health	$1.71B	$7.23	34.12	17.73	1.49	0.67%	-98.53%	4.69%	10/29/2026 (Estimated)
COR Cencora	$1.55B	$13.46	24.56	16.72	1.91	0.79%	125.45%	4.18%	11/4/2026 (Estimated)
CVS CVS Health	$1.77B	$3.78	25.61	11.40	0.95	1.18%	13.12%	3.95%	11/4/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	31.88	21.49	2.66	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
MCK McKesson	$4.76B	$37.37	24.28	18.21	1.83	1.12%	-253.21%	5.90%	11/4/2026 (Estimated)
SAN Banco Santander	$15.95B	$1.23	12.11	10.42	0.74	26.94%	12.43%	0.75%	10/28/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	23.16	8.41	1.34	8.66%	14.19%	7.95%	10/23/2026 (Estimated)
SNYNF Sanofi	N/A	$3.08	28.94	N/A	N/A	N/A	N/A	N/A	10/30/2026 (Estimated)
TEV Tervita	N/A	-C$0.01	N/A	N/A		N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	60.60	12.08	4.57	4.08%	32.64%	6.34%	11/4/2026 (Estimated)

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q4 2026	CAH Cardinal Health	$2.42	$2.91	+$0.49	$1.70	$65.15 billion	$63.67 billion
8/5/2026	Q3 2026	COR Cencora	$4.35	$4.48	+$0.13	$3.94	$84.31 billion	$84.75 billion
8/5/2026	Q2 2026	CVS CVS Health	$1.87	$2.58	+$0.71	$2.31	$100.03 billion	$106.10 billion
8/5/2026	Q1 2027	MCK McKesson	$9.56	$9.93	+$0.37	$5.15	$103.88 billion	$105.38 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
7/22/2026	Q2 2026	SAN Banco Santander	$0.29	$0.27	-$0.02	$0.26	$17.90 billion	$17.93 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAH Cardinal Health	$2.06	0.84%	-4.74%	28.49%	29 Years
COR Cencora	$2.40	0.73%	+5.79%	17.83%	15 Years
CVS CVS Health	$2.66	2.75%	+5.87%	70.37%	4 Years
JNJ Johnson & Johnson	$5.36	1.95%	+5.25%	62.11%	64 Years
MCK McKesson	$3.76	0.41%	+13.68%	10.06%	17 Years
SAN Banco Santander	$0.21	1.41%	N/A	17.07%	N/A
SNY Sanofi	$1.76	3.98%	+6.46%	92.15%	N/A
SNYNF Sanofi	$2.80	3.14%	N/A	90.78%	N/A
TEV Tervita	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/10/2026	CAH Cardinal Health	quarterly	$0.5158	0.86%	10/1/2026	10/1/2026	10/15/2026
7/21/2026	MCK McKesson	quarterly	$0.94	0.41%	9/1/2026	9/1/2026	10/1/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
8/3/2026	COR Cencora	quarterly	$0.60	0.76%	8/14/2026	8/14/2026	8/31/2026
7/10/2026	CVS CVS Health	quarterly	$0.6650	2.49%	7/23/2026	7/23/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAH Cardinal Health	N/A	0.88	0.49
COR Cencora	3.53	0.93	0.58
CVS CVS Health	0.74	0.87	0.66
JNJ Johnson & Johnson	0.44	1.09	0.81
MCK McKesson	N/A	0.89	0.52
SAN Banco Santander	N/A	0.24	0.24
SNY Sanofi	0.21	0.99	0.64
SNYNF Sanofi	N/A	N/A	N/A
TEV Tervita	440.44	1.00	0.86
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAH Cardinal Health	87.17%
COR Cencora	97.52%
CVS CVS Health	80.66%
JNJ Johnson & Johnson	69.55%
MCK McKesson	85.07%
SAN Banco Santander	9.19%
SNY Sanofi	14.03%
SNYNF Sanofi	30.06%
TEV Tervita	N/A
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
CAH Cardinal Health	0.12%
COR Cencora	0.38%
CVS CVS Health	0.85%
JNJ Johnson & Johnson	0.16%
MCK McKesson	0.06%
SAN Banco Santander	9.48%
SNY Sanofi	1.00%
SNYNF Sanofi	N/A
TEV Tervita	N/A
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAH Cardinal Health	63,900	232.58 million	232.30 million	Optionable
COR Cencora	51,000	190.83 million	190.10 million	Optionable
CVS CVS Health	300,000	1.28 billion	1.27 billion	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
MCK McKesson	43,000	116.59 million	116.52 million	Optionable
SAN Banco Santander	198,403	14.69 billion	13.30 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
SNYNF Sanofi	91,600	N/A	N/A	Not Optionable
TEV Tervita	36,800	115.66 million	N/A	Not Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Headlines

Recent News About These Companies

Nykredit A S Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 5 at 5:11 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Analysts

September 5 at 4:28 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - Slideshow

September 4 at 7:08 PM | seekingalpha.com

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

September 4 at 3:49 PM | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group

September 4 at 2:41 PM | marketbeat.com

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 4 at 11:50 AM | financialpost.comF

Teva Pharmaceutical Industries Ltd. Upgraded to Investment-Grade by S&P Global Ratings

September 4 at 11:50 AM | quiverquant.comQ

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 4 at 11:30 AM | globenewswire.com

Russian forces strike major pharmaceutical warehouse twice in one day

September 4 at 8:56 AM | msn.com

Teva Advances NYSE Listing With ADS Exchange Plan

September 3 at 6:51 PM | tipranks.com

Outperforming Pharma Stock Still Has Upside Potential

September 3 at 5:55 PM | finance.yahoo.com

Outperforming Pharma Stock Still Has Upside Potential

September 3 at 2:29 PM | schaeffersresearch.com

TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

September 3 at 12:54 PM | finance.yahoo.com

TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

September 3 at 12:26 PM | zacks.com

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

September 2 at 8:12 PM | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript

September 2 at 5:00 PM | seekingalpha.com

Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

September 2 at 3:11 PM | finance.yahoo.com

Teva’s mAb shows benefit in celiac disease study

September 2 at 3:11 PM | clinicaltrialsarena.comC

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

September 2 at 10:10 AM | rttnews.com

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

September 2 at 10:10 AM | finance.yahoo.com

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

September 2 at 10:01 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Company Descriptions

Cardinal Health NYSE:CAH

$246.67 -1.94 (-0.78%)

As of 09/4/2026 03:58 PM Eastern

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Cencora NYSE:COR

$330.52 -6.70 (-1.99%)

As of 09/4/2026 03:58 PM Eastern

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

CVS Health NYSE:CVS

$96.80 -0.40 (-0.41%)

As of 09/4/2026 03:58 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Johnson & Johnson NYSE:JNJ

$275.12 -3.31 (-1.19%)

As of 09/4/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

McKesson NYSE:MCK

$907.35 -14.03 (-1.52%)

As of 09/4/2026 03:58 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Banco Santander NYSE:SAN

$14.90 -0.15 (-1.00%)

As of 09/4/2026 03:58 PM Eastern

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Sanofi NASDAQ:SNY

$44.24 -0.09 (-0.20%)

As of 09/4/2026 04:00 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi OTCMKTS:SNYNF

$89.27 0.00 (0.00%)

As of 09/4/2026

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Tervita TSE:TEV

Tervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.

Teva Pharmaceutical Industries NYSE:TEVA

$36.36 -0.26 (-0.71%)

As of 09/4/2026 03:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Earnings

Compare Dividends

Latest TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TEV, CAH, COR, CVS, JNJ, MCK, SAN, SNYNF, SNY, and TEVA Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools